Literature DB >> 3084248

Effect of increasing doses of amikacin with or without piperacillin in the serum bactericidal test.

H Lagast, A Pascual-Lopez, P Dejace, J Klastersky.   

Abstract

To determine whether high doses of amikacin would prevent the development of resistance in clinical isolates, the serum bactericidal activity and killing rate of conventional and high doses of amikacin and piperacillin alone and in combination were measured in volunteer sera against a series of ten strains each of Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Amikacin serum levels were 24.9 +/- 6.0 mg/l 1 h after infusion of the 7.5 mg/kg dose and 44.8 +/- 5.0 mg/l after the two-fold dose. Median serum bactericidal titers for low dose piperacillin + amikacin were 1:8-1:64 and for high-dose piperacillin + amikacin 1:16-1:128. Both were satisfactory, except against piperacillin-resistant Pseudomonas aeruginosa (median bactericidal titers less than or equal to 1:2), and both combinations had equivalent killing rates.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084248     DOI: 10.1007/bf02013477

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  17 in total

1.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

2.  Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

Authors:  J P Sculier; J Klastersky
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

3.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

4.  Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group.

Authors:  S C Schimpff; H Gaya; J Klastersky; M H Tattersall; S H Zinner
Journal:  J Infect Dis       Date:  1978-01       Impact factor: 5.226

5.  The carbenicillin-gentamicin combination against Pseudomonas aeruginosa. Correlation of effect with gentamicin sensitivity.

Authors:  R M Kluge; H C Standiford; B Tatem; V M Young; S C Schimpff; W H Greene; F M Calia; R B Hornick
Journal:  Ann Intern Med       Date:  1974-11       Impact factor: 25.391

6.  Plasma concentration monitoring of aminoglycosides.

Authors:  F Follath; M Wenk; S Vozeh
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

7.  Effects of the combination of gentamicin and carbenicillin on the bactericidal activity of serum.

Authors:  J Klastersky; G Vamecq; R Cappel; G Swings; L Vandenborre
Journal:  J Infect Dis       Date:  1972-02       Impact factor: 5.226

8.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

9.  Risk factors for nephrotoxicity in patients treated with aminoglycosides.

Authors:  R D Moore; C R Smith; J J Lipsky; E D Mellits; P S Lietman
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

10.  Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.

Authors:  L G Reimer; S Mirrett; L B Reller
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

View more
  1 in total

1.  Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa.

Authors:  D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.